

# CANCER ANTIBODIES VACCINES/ADJUVANTS & DELIVERY

17-19 September 2014, University of Lausanne/CHUV, Lausanne, Switzerland

# FINAL ORAL PROGRAMME & POSTER PROGRAMME CAVAD 2014

## SCIENTIFIC ADVISORY PANEL

Conference Co-Chairs: Lindy Durrant (*University of Nottingham, Nottingham, UK*)  
and Daniel Speiser (*Ludwig Institute/University of Lausanne, Lausanne, Switzerland*)

Martin J. Glennie (*University of Southampton, Southampton, UK*)

Haval Shirwan (*University of Louisville, Louisville, Kentucky, USA*)

Peter L. Stern (*University of Manchester, Manchester, UK*)

Simon Draper (*University of Oxford, Oxford, UK*)

Dietmar Zehn (*CHUV, Lausanne, Switzerland*)

Mark C. Glassy (*IMRF, San Diego, California, USA*)

Jeffrey A. Hubbell (*EPFL, Lausanne, Switzerland*)

John Lambert (*ImmunoGen Inc., Waltham, Massachusetts, USA*)

Alena Donda (*University of Lausanne, Lausanne, Switzerland*)




Niranjan Sardesai (*Inovio Inc., Blue Bell, Pennsylvania, USA*)

John Haurum (*F-star, Cambridge, UK*)

Francois Spertini (*CHUV, Lausanne, Switzerland*)

Ronald Rooke (*ElsaLys Biotech, Illkirch, France*)

John-Edward Butler-Ransohoff (*Bayer Innovation GmbH, Leverkusen, Germany*)



08.45 Onwards

Registration

09.55-10.00

**Welcome to Lausanne & Opening Remarks**

Daniel E. Speiser

*(University of Lausanne, Lausanne, Switzerland)*

**SESSION 1:  
OPENING PLENARY**

Moderator: Daniel E. Speiser

*(University of Lausanne, Lausanne, Switzerland)*

10.00-10.45

**'Role of IL-1a in Cancer'**

Thomas M. Kundig

*(University Hospital Zurich, Zurich, Switzerland)*

10.45-11.30

**'Lessons from immunotherapeutic developments against 5T4 oncofoetal antigen'**

Peter Stern

*(University of Manchester, Manchester, UK)*

11.30-12.00

**'Phase I/II trial of a novel antibody DNA immunotherapy, targeting CD64, in the treatment of melanoma'**

Lindy Durrant

*(University of Nottingham, Nottingham, UK)*

12.00-12.30

**'Towards a glioma vaccine'**

Virgil Schijns

*(Epitopoietic Research Corporation (ERC) / University of Wageningen, Wageningen, The Netherlands)*

12.30-14.00

Lunch Break

**SESSION 2:  
PLENARY**

Moderator: Lindy Durrant

*(University of Nottingham, Nottingham, UK)*

14.00-14.30

**'Vaccination against cancer, present and future'**

Daniel E. Speiser

*(University of Lausanne, Lausanne, Switzerland)*

14.30-15.00

**'Reverse proteomics for the discovery of novel cancer biomarkers and mAb therapies'**

Guido Grandi

*(Novartis vaccines, Siena, Italy)*

15.00-15.30

**'Obinutuzumab (GAZYVARO): A novel glycoengineered type II CD20 antibody for the treatment of chronic lymphocytic leukemia (CLL)'**

Christian Klein

*(Roche Pharmaceutical Research and Early Development, Roche Innovation Center, Zurich, Switzerland)*

15.30-15.45

Tea Break

**SESSION 3:  
ANTIBODIES FOR CANCER THERAPY**

Moderator: Mark C. Glassy

*(Nascent Biotech, Inc., San Diego, California, USA)*

15.45-16.15

**'KK1, a natural humabn IgM for adenocarcinomas'**

Mark C. Glassy

*(Nascent Biotech, Inc. / Integrated Medical Sciences Association Foundation, San Diego, California, USA)*

16.15-16.35

**'Novel anti-glycolipid mabs for tumour therapy'**

Mireille Vankemmelbeke

*(University of Nottingham, Nottingham, UK)*

16.35-16.55

**'Generation and functional characterization of synthetic antibodies specific to colon cancer stem cell antigens'**

Jason Moffat

*(University of Toronto, Toronto, Canada)*

16.55-17.15

**'Novel mechanism of action of anti-CTLA-4 mAb therapy in patients with advanced melanoma'**

Emanuela Romano

*(University of Lausanne, Lausanne, Switzerland)*

17.15-17.45

**'Personalized vector vaccines expressing neoepitopes'**

Lukas Flatz

*(Institute of Immunobiology, Kantonsspital St. Gallen, Switzerland)*

## SESSION 4: ANTIBODY-DRUG CONJUGATES/NANOCARRIERS

Moderator: Haval Shirwan  
(University of Louisville, Louisville, Kentucky, USA)

09.00-09.30

**'Development of enzymatically conjugated next-generation ADCs for the treatment of cancer'**

Roger Beerli  
(NBE-Therapeutics LLC, Basel, Switzerland)

9.30-10.00

**'Breakthrough nanocarriers to discover new vaccine strategies for cancer immunotherapy'**

Gilles Besin, Emilie Goudeau, Berangere Evrard and Bruno Pitard  
(In-Cell-Art, Nantes, France)

10.00-10.20

**'The discovery of novel vaccines, ADCs, and bispecific immunomodulator antibodies using cell-free expression (Xpress CF/Xpress CF+)'**

Aaron K. Sato  
(Sutro Biopharma, South San Francisco, California, USA)

10.20-11.00

Coffee Break

## SESSION 5: IMMUNE RESPONSE

Moderator: Anna Mondino  
(San Raffaele Scientific Institute, Milano, Italy)

11.00-11.30

**'Can vaccines be developed from the natural anti-cancer immune response?'**

Mark C. Glassy  
(Nascent Biotech, Inc. / Integrated Medical Sciences Association Foundation, San Diego, California, USA)

11.30-12.00

**'Cancer therapy exploiting cytolytic T lymphocytes'**

Nathalie Rufer, P.O. Gannon, E.M. Lancu, A. Huber, P. Baumgartner and D.E. Speiser  
(University of Lausanne, Lausanne, Switzerland)

12.00-12.20

**' $\alpha$ -Fetoprotein encoding DNA/Nanotaxi<sup>®</sup> vaccination induces specific immune responses leading to impaired growth of autochthonous hepatocellular carcinoma in mice model'**

Gilles Besin, Berangere Evrard, Jean-Paul Tudor, Emilie Goudeau, Sophie Conchon and Bruno Pitard  
(In-Cell-Art, Nantes, France)

12.20-12.40

**'Gene polymorphisms predicting different immune responses to cancer vaccines'**

Yolande Saab  
(Lebanese American University, Byblos, Lebanon)

12.40-14.00

Lunch Break

## SESSION 6: VACCINATION & IMMUNOTHERAPY

Moderator: To be confirmed

14.00-14.30

**'Efficacy and PET monitoring of rationally designed immunotherapy of cancer based on an alphavirus replicon vaccine'**

Toos Daemen  
(University Medical Center, Groningen, The Netherlands)

14.30-14.55

**'Safety and efficacy of a genetic vaccine targeting Telomerase against various canine cancers'**

Luigi Aurisicchio, Alessandra Gavazza, George Lubas, Eliana Greissworth, David Jemiolo and Gennaro Ciliberto  
(Takis Biotech, Rome, Italy)

14.55-15.20

**'Valuing upstream targets for passive immunotherapy'**

Ronald Rooke  
(Elsalys Biotech, Lyon, France)

15.20-16.00

Tea Break

## SESSION 7: COMBINATION THERAPY TOPICS

Moderator: Daniel Speiser  
(University of Lausanne, Lausanne, Switzerland)

16.00-16.30

**'Combined tumor/tumor-stroma targeting in adoptive T cell therapy of solid tumors'**

Anna Mondino  
(San Raffaele Scientific Institute, Milano, Italy)

16.30-17.00

**'Self-adjuvanted RNAActive<sup>®</sup> vaccines provide a promising platform for combination therapies with checkpoint inhibitors'**

Regina Heidenreich, Aleksandra Kowalczyk, Edith Jasny, Fatma Doner, Stephen M. Huber and Mariola Fotin-Mleczek  
(CureVac GmbH, Tübingen, Germany)

## SESSION 8: ADJUVANTS & VACCINE AMPLIFIERS

Moderator: Peter Stern

*(University of Manchester, Manchester, UK)*

09.00-09.30

### 'Adjuvants for cancer vaccines: Timing is everything'

Carole Bourquin

*(University of Fribourg, Fribourg, Switzerland)*

09.30-10.00

### 'SA-4-1BBL as a platform to develop adjuvant systems for therapeutic cancer vaccines'

Haval Shirwan

*(University of Louisville, Louisville, Kentucky, USA)*

10.00-10.30

### 'CD1d-restricted iNKT cells as adjuvant to harness innate and adaptive antitumor immunity'

Alena Donda

*(University of Lausanne, Lausanne, Switzerland)*

10.30-10.50

### 'Adjuvantation of immunotherapeutic treatment with MVA-MUC1 in preclinical cancer models'

Karola Rittner, Laetitia Fend, Emmanuelle Schaedler, Julie Hortelano,

Tanja Gatard, Jacqueline Kintz, Sandrine Cochin, Marie-Christine

Claudepierre, Muriel Gantzer and Xavier Preville

*(Transgene SA, Illkirch-Graffenstaden, France)*

10.50-11.05

Coffee Break

## SESSION 9: TECHNIQUES AND STRATEGIES

Moderator: Lindy Durrant

*(University of Nottingham, Nottingham, UK)*

11.05-11.30

### 'Photochemical internalization (PCI) – A new immune-potentiating technology for stimulating cytotoxic T-cell responses'

Pal Kristian Selbo, Gael L'Heveder, Anders Hogset, Monika Hakerud,

Thomas M. Kundig and Pal Johansen

*(PCI Biotech, Lysaker, Norway)*

11.30-11.50

### 'Engineering immune responses to HPV related disease'

Mark Bargarazzi

*(Inovio Inc, Blue Bell Pennsylvania, USA)*

11.50-12.10

### 'In vivo electroporation: A versatile and multitask technology to fight cancer'

Luigi Aurisicchio, Emanuele Marra, Giuseppe Roscilli, Laura Luberto,

Manuela Cappelletti and Gennaro Ciliberto

*(Takis Biotech, Rome, Italy)*

12.10-12.30

### 'Laser-assisted intradermal delivery of XCR1-targeted vaccines to XCR1+ dermal DCs leads to melanoma eradication'

Dorothea Terhorst

*(Charité – Medical University of Berlin, Berlin, Germany)*

12.30

### Closing Remarks & Departure

Lindy Durrant

*(University of Nottingham, Nottingham, UK)*

## POSTER SESSION

Poster 101

### 'Stability characteristics of rabies vaccine with squalene adjuvant'

A. Ondrejko et al.

*(University of Veterinary Medicine & Pharmacy, Koscic, Slovak Republic)*

Poster 102

### 'Does alpha-tocopherol protect the squalene adjuvant?'

J Suli et al.

*(University of Veterinary Medicine & Pharmacy, Koscic, Slovak Republic)*

Poster 103

### 'Challenges from design of proteins to cell line development'

E. Prost et al.

*(Advanced BioDesign, Saint-Priest, France)*

Poster 104

*To be confirmed*

\* This final programme is correct at the time of printing. However the organizers reserve the right to make any alterations that may be required in the interests and integrity of the final conference programme.